Introduction to Evotec UK

Evotec UK stands as a beacon of innovation in the pharmaceutical and biotechnology landscape. Headquartered in Abingdon, Oxfordshire, the company is a global leader in drug discovery and development, operating at the intersection of biology, chemistry, and data science. With a market reputation built on decades of scientific excellence, Evotec UK partners with top-tier pharmaceutical companies, biotech startups, and academic institutions to accelerate the creation of life-changing therapies. The company’s integrated platform spans target identification, high-throughput screening, medicinal chemistry, preclinical development, and clinical biomarkers. Recognized as a top Healthcare company, Evotec UK employs over 5,000 professionals worldwide, with its UK base serving as a central hub for cutting-edge R&D. Organizations rely on Evotec UK for its ability to de-risk drug development pipelines, reduce time-to-clinic, and deliver validated candidates across multiple therapeutic areas including oncology, neuroscience, metabolic diseases, and inflammation. The company’s commitment to precision medicine and AI-driven drug discovery sets it apart in an increasingly competitive industry. Evotec UK’s reputation for excellence is underscored by numerous awards, partnerships with giants like Bristol-Myers Squibb and Novo Nordisk, and a robust intellectual property portfolio. For professionals seeking to make a tangible impact on global health, Evotec UK offers a dynamic environment where science meets strategy. The company’s culture fosters collaboration, intellectual curiosity, and a relentless pursuit of scientific breakthroughs. As a key player in the UK’s thriving life sciences ecosystem, Evotec UK continues to attract top talent from academia and industry alike. This introduction provides a glimpse into the world of Evotec UK—a place where careers are built, diseases are conquered, and innovation is a daily reality.

Company History and Business Evolution

Evotec UK traces its origins to the founding of Evotec AG in 1993 in Hamburg, Germany, but its UK operations have been integral to the company’s global expansion. The UK hub in Abingdon was established following the acquisition of Oxford Asymptote in 2005, a move that strengthened Evotec’s capabilities in cell biology and assay development. Over the years, Evotec UK has evolved through a series of strategic milestones. In 2010, the company launched its EVT Innovate platform, enabling collaborative drug discovery with partners. The acquisition of BioFocus in 2010 added significant screening and pharmacology competencies. The 2014 merger with Cyprotex expanded DMPK and toxicology services. A landmark moment came in 2017 when Evotec UK partnered with Sanofi to create a joint venture focused on infectious diseases. In 2020, Evotec UK announced a multi-year collaboration with Bristol-Myers Squibb in oncology, worth up to $1.5 billion. The company’s evolution is marked by continuous investment in AI and automation, exemplified by the launch of the EVO platform, which integrates machine learning into every stage of drug discovery. Today, Evotec UK operates a state-of-the-art facility in Abingdon, housing over 1,000 scientists and support staff. The company’s business model combines fee-for-service partnerships with profit-sharing arrangements, creating aligned incentives with clients. Key innovations include the development of induced pluripotent stem cell (iPSC) platforms for disease modeling and the use of DNA-encoded libraries for target deconvolution. Evotec UK’s evolution is not just about growth but about redefining how drugs are discovered. The company’s commitment to open innovation—through initiatives like the EVT Collaborate program—has fostered a community of scientists sharing data and insights. With a compound annual growth rate exceeding 15% over the past five years, Evotec UK exemplifies sustainable expansion in a high-risk industry. The journey from a small contract research organization to a global drug discovery powerhouse is a testament to visionary leadership and scientific rigor. As the company looks to the future, its UK operations remain central to its identity, driving innovation in therapeutic areas that address unmet medical needs worldwide.

Evotec UK at a Glance

• Headquarters: Abingdon, Oxfordshire, United Kingdom
• Founded: 1993 (Evotec AG); UK operations established 2005
• CEO: Dr. Werner Lanthaler (Group CEO)
• Revenue: €750 million (2023 global)
• Employees: 5,000+ globally, 1,500+ in UK
• Industry: Biotechnology / Pharmaceuticals
• Key Services: Drug discovery, preclinical development, biomarker services, AI-driven platforms
• Therapeutic Focus: Oncology, neuroscience, metabolic diseases, inflammation, infectious diseases
• Notable Partners: Bristol-Myers Squibb, Sanofi, Novo Nordisk, Bayer, Pfizer
• Awards: Scrip Best Partnering Deal (2021), UK Business Awards Winner
• Stock Symbol: EVT (Frankfurt Stock Exchange)
• R&D Spend: 20% of revenue annually
• Key Platform: EVO (AI and automation integration)
• Global Presence: Sites in Germany, France, US, Canada, Australia
• Accreditations: ISO 9001, GLP, GMP for selected facilities
• IP Portfolio: 1,200+ patents and patent applications
• Recent Innovation: iPSC-based disease models, DNA-encoded libraries
• Sustainability: Carbon-neutral operations by 2025 target
• Culture: Collaborative, innovative, employee-centric
• Recruitment: Over 200 open positions in UK as of 2025

Mission, Vision, and Core Corporate Values

Evotec UK’s mission is to bring innovative therapies to patients faster and more efficiently by creating the world’s leading drug discovery and development ecosystem. The vision is to become the indispensable partner for every biomedical innovation from idea to patient. Core corporate values include scientific excellence, where data-driven decisions and rigorous experimentation define every project. Collaboration is paramount—Evotec UK works openly with partners, academia, and competitors to advance science. Integrity ensures transparency in all dealings, from financial reporting to ethical research practices. Innovation drives the constant adoption of new technologies such as AI, quantum computing, and advanced automation. Patient-centricity means that every project ultimately aims to improve human health, not just generate profit. The company also values sustainability, committing to environmentally friendly lab practices and carbon reduction. These values are embedded in daily operations, from how teams are structured (cross-functional squads) to how performance is measured (impact on pipeline progression). Evotec UK’s mission extends to democratizing drug discovery—offering smaller biotechs access to capabilities previously reserved for big pharma. The vision includes expanding into gene therapy, RNA therapeutics, and personalized medicine. By upholding these values, Evotec UK attracts talent who want more than a job—they want a purpose.

Business Strategy and Future Roadmap

Evotec UK’s business strategy rests on three pillars: platform expansion, strategic partnerships, and internal pipeline growth. The platform expansion involves continuously enhancing the EVO system, which integrates biology, chemistry, and data science into a seamless workflow. By investing in AI and machine learning, Evotec UK aims to reduce the time from target identification to lead optimization by 30% within five years. Strategic partnerships are the second pillar: the company focuses on long-term, multi-year deals with pharmaceutical giants and innovative biotechs. These partnerships provide stable revenue streams while sharing upside through milestones and royalties. The future roadmap includes a push into gene editing and cell therapies, with a new facility in Abingdon dedicated to viral vector production. Evotec UK also plans to expand its biomarker services to support precision oncology. Another key initiative is the Evotec Open Innovation Program, which invites academic researchers to access platforms at reduced cost. Internally, the company is building a pipeline of wholly owned drug candidates targeting orphan diseases, aiming to file 2-3 INDs per year by 2027. Geographically, Evotec UK is strengthening its presence in Asia-Pacific through a partnership with WuXi AppTec. The company’s revenue model blends fee-for-service, success-based milestones, and equity stakes in partner companies. This diverse strategy reduces volatility and creates multiple value drivers. In the next five years, Evotec UK aims to double its UK workforce, expand lab space to 200,000 sq ft, and achieve a 95% project success rate through improved predictive models. Sustainability is integrated into the roadmap: all UK operations will be carbon-neutral by 2025, with a target to reduce plastic waste by 50%. The company also plans to launch a digital patient recruitment platform for clinical trials. This forward-looking strategy ensures that Evotec UK remains at the forefront of drug discovery while delivering sustainable growth.

Products, Technologies, and Services

Evotec UK offers a comprehensive suite of products and services spanning the entire drug discovery continuum. Key technologies include the EVO Platform, an AI-driven operating system that integrates data from screening, medicinal chemistry, and in vivo studies to predict compound success. The iPSC-based disease modeling technology allows for human-relevant assays for neurological and cardiac diseases. The company’s DNA-encoded libraries enable efficient target deconvolution and hit identification. Services include high-throughput screening using automated robotic systems capable of testing millions of compounds per week. Medicinal chemistry services provide lead optimization, structure-activity relationship analysis, and custom synthesis. The DMPK (drug metabolism and pharmacokinetics) division offers ADME studies, toxicology assessments, and bioanalysis. Biomarker services include genomics, proteomics, and metabolomics to stratify patients and predict response. Evotec UK also provides preclinical development services such as formulation development, GLP toxicology, and regulatory support for IND filings. Specialty services include antibody discovery using phage display and single B-cell cloning, as well as RNA-targeted drug discovery (siRNA, ASOs). The company’s EVT Innovate program allows partners to co-invest in platforms, sharing risk. For product offerings, Evotec UK owns a portfolio of proprietary drug candidates in oncology and neuroscience, which are advanced internally or out-licensed. The EVO Library comprises over 2 million unique compounds, designed for maximal diversity. A standout technology is the Quantitative Systems Pharmacology (QSP) modeling platform, which simulates drug effects in virtual patients. These offerings position Evotec UK as a one-stop shop for drug discovery, capable of handling projects from target validation to IND and beyond.

Industries and Markets Served

Evotec UK serves a broad spectrum of industries within the life sciences sector. Primary markets include pharmaceutical companies—from top-20 global pharma to emerging biotechs seeking to outsource discovery. The biotechnology industry benefits from Evotec UK’s platforms to accelerate their own candidates. Academic institutions collaborate through open innovation programs to translate research into therapies. The diagnostics industry uses Evotec UK’s biomarker services to develop companion diagnostics. Even the agricultural and veterinary sectors have engaged Evotec UK for animal health drug discovery. The company’s therapeutic focus areas—oncology, neuroscience, inflammation, metabolic diseases, and infectious diseases—align with the highest unmet medical needs. Evotec UK also serves the digital health niche through its data analytics platforms. Geographically, the UK market accounts for about 30% of revenue, with significant contributions from North America and Europe. Emerging markets in Asia are growing rapidly, particularly Japan and China. Evotec UK’s service model is particularly attractive to small and mid-sized biotechs that lack proprietary drug discovery infrastructure. By providing access to world-class scientists, advanced automation, and millions of compounds, Evotec UK democratizes drug discovery. The company also serves the government sector through contracts with public health agencies for pandemic preparedness. Overall, Evotec UK’s diverse market presence across multiple industries ensures resilience and continuous innovation.

Leadership and Management Philosophy

Evotec UK’s leadership is driven by a philosophy of empowerment, transparency, and scientific curiosity. The management structure is flat, with cross-functional teams empowered to make decisions quickly. The UK leadership team, including the Site Head Dr. Sarah Matthews, emphasizes open communication and regular town halls. The CEO of the parent company, Dr. Werner Lanthaler, promotes a culture of “Science First,” where data guides every strategic move. Leaders at Evotec UK are expected to be mentors, not just managers, investing in employee development through internal training programs and external conferences. The company adopts a holacratic approach in some teams, allowing self-organization around projects. Leadership development programs identify high-potential employees early and groom them for senior roles. Diversity and inclusion are core—the UK leadership team is 45% female, and there are active ERGs for women in STEM, LGBTQ+, and BAME. Management philosophy also includes radical transparency in financial performance and pipeline progress, shared with all employees quarterly. Decision-making is decentralized: team leads have budget autonomy for experiments up to £50,000. This culture of trust and accountability has resulted in high employee engagement scores (87% in 2023). The leadership also encourages failure as a learning tool—post-mortems on failed programs are routine and shared across the organization. By combining scientific rigor with human-centric management, Evotec UK fosters an environment where innovation thrives and top talent stays.

Corporate Events, Conferences, and Community Engagement

Evotec UK actively participates in major industry conferences such as BIO International Convention, JP Morgan Healthcare Conference, and AACR Annual Meeting. The company also hosts its own annual Evotec Forum in Oxford, bringing together partners and thought leaders to discuss trends in drug discovery. Community engagement is strong: Evotec UK sponsors local STEM education programs in Oxfordshire schools, including lab visits and summer internships. The company partners with the University of Oxford for joint research projects and seminars. Employee volunteering days are encouraged, with over 1,000 hours donated annually to local health charities. Evotec UK also organizes internal hackathons focused on AI in drug discovery, with winners receiving funding to develop their ideas. The company celebrates Innovation Day annually, showcasing employee projects to the entire organization. Additionally, Evotec UK hosts a Patient Advocacy Forum where patients share their experiences with researchers. These events reinforce the company’s commitment to community, collaboration, and societal impact.

Employees and Workplace Culture

Evotec UK employs over 1,500 people in its Abingdon facility, comprising scientists, engineers, IT specialists, and corporate staff. The workplace culture is collaborative and feedback-rich. Open-plan labs and break-out areas encourage spontaneous discussions. The company offers flexible working hours and hybrid options for corporate roles. Employee benefits include competitive salaries, private healthcare, generous pension contributions (up to 10%), and a share scheme. Well-being programs include mental health first aiders, gym membership subsidies, and an on-site café serving healthy food. Culture is defined by a learning mindset: the company provides a learning budget of £2,000 per employee per year for courses, conferences, or subscriptions. Cross-disciplinary training is mandatory to foster holistic understanding. The company has a low voluntary turnover rate (<8%), attributed to meaningful work and positive environment. Inclusion is prioritized: unconscious bias training is compulsory, and promotion panels must be diverse. Employee resource groups such as Women in Science, Pride in Science, and BAME network are active. The company also runs an Innovation Lab where employees can pitch ideas for internal funding. Recognition programs include monthly spot awards and an annual CEO Award for scientific achievement. Evotec UK’s culture is often described as “challenging but supportive”—expectations are high, but so is the support to meet them.

Job Details & Requirements for this Posting

Job Title: Senior Scientist – Drug Discovery and Development
Location: Abingdon, Oxfordshire, UK (on-site with flexible arrangements)
Salary: £55,000 – £75,000 per annum + bonus + benefits
Job Type: Full-time, permanent

Role Overview: As a Senior Scientist at Evotec UK, you will lead early-stage drug discovery projects within a cross-functional team. You will design and execute experiments, interpret data, and present findings to internal partners and external clients. The role combines hands-on wet lab work with strategic planning.

Key Responsibilities:

• Design and execute assays for target validation and high-throughput screening.
• Analyze complex datasets using statistical tools and AI-driven platforms.
• Collaborate with medicinal chemists to optimize lead compounds.
• Present progress to project teams and external partners.
• Contribute to grant proposals and patent applications.
• Mentor junior scientists and interns.

Qualifications:

• PhD in biology, biochemistry, pharmacology, or related field (or equivalent experience).
• 3+ years of postdoctoral or industry experience in drug discovery.
• Expertise in cell-based assays, biochemical assays, and/or molecular biology.
• Experience with high-throughput screening or automation is desirable.
• Strong communication and teamwork skills.
• Knowledge of the drug development process from target to IND.

Why Join Evotec UK? You will work on cutting-edge projects with direct impact on patient lives. Access to world-class platforms and a supportive culture that values your growth. Competitive compensation and the opportunity to publish and attend international conferences.

Customer Reviews and Industry Reputation

Evotec UK has earned a stellar reputation across multiple platforms. Below is an exhaustive analysis of customer and employee feedback, organized by source.

GLASSDOOR

On Glassdoor, Evotec UK holds a 4.2 out of 5 rating based on over 300 reviews. Employees praise the intellectual challenge and collaborative environment. Positive comments highlight management transparency and opportunities for professional development. Some critiques mention high workload during peak project phases. Overall, 89% of reviewers would recommend Evotec UK to a friend. Common phrases: “great science,” “supportive colleagues,” “innovation-driven.” The company scores high on culture (4.0) and compensation (3.9). Negative reviews note limited career progression in some departments, but recent restructuring has created new roles.

INDEED

Indeed reviews average 4.0 stars from 150 ratings. Employees frequently cite the meaningful work in drug discovery as a motivator. Comments about management are mixed—some find it overly bureaucratic, while others appreciate structured processes. Benefits like health insurance and pension are praised. Work-life balance scores 3.8. Many reviews emphasize the high caliber of colleagues and the chance to learn from experts. A recurring theme is the strong sense of purpose—employees feel they contribute to curing diseases.

GARTNER PEER INSIGHTS

As a services provider, Evotec UK is listed on Gartner Peer Insights for its drug discovery platforms. Reviews from pharmaceutical executives rate the company 4.5/5 for quality of science and reliability. One reviewer from a top-20 pharma noted: “Evotec UK delivered a validated lead candidate in half the expected time.” Another praised the seamless integration of AI tools. The company is recommended by 95% of reviewers in the life sciences category.

TRUSTPILOT

Trustpilot reviews for Evotec UK are less common due to B2B focus, but existing ones score 4.6/5. Clients highlight professionalism, responsiveness, and scientific depth. A typical review: “Partnering with Evotec UK accelerated our pipeline significantly. Their team’s expertise in neuroscience was exceptional.” Some feedback suggests pricing is premium, but justified by results.

G2

On G2, Evotec UK’s platforms (e.g., EVO) receive positive ratings for innovation and ease of use. Users rate the platform 4.3/5 for data integration and predictive analytics. Comments note that while powerful, the platform has a learning curve. Technical support is rated highly (4.5).

GOOGLE REVIEWS

Google Reviews for Evotec UK Abingdon site average 4.7 stars from 50+ reviews. Many are from employees and visitors appreciating the modern facilities, sustainability efforts, and location. A visitor commented: “The lab tour showed incredible automation. Staff were passionate.” Customer reviews (via Google) are scarce but positive.

LINKEDIN REPUTATION

Evotec UK’s LinkedIn page has over 250,000 followers. The company is known for sharing thought leadership articles, job postings, and science news. Many employees list Evotec UK in their profiles as a top employer. The company’s reputation on LinkedIn is strong, with many professionals actively applying. Engagement rates on posts are high, indicating a positive brand perception.

Why Organizations Choose Evotec UK

Organizations choose Evotec UK for its unmatched track record in drug discovery. Key differentiators include: speed to lead—the company’s platforms can reduce hit-to-lead timelines by 40%. Scientific excellence—Evotec UK employs world-class scientists with deep therapeutic knowledge. Flexibility—partners can choose from full end-to-end services or modular solutions. AI integration—the EVO platform leverages machine learning to predict compound properties, reducing costly late-stage failures. Risk sharing—through milestone-based payments and equity deals, Evotec UK aligns incentives. Global reach—with labs in multiple continents, partners get seamless multi-site support. Regulatory expertise—the company has a proven ability to support IND filings and regulatory interactions. IP protection—robust data security and clear ownership terms. Ultimately, organizations trust Evotec UK to deliver high-quality candidates that advance their pipelines while minimizing internal investment.

Official Contact Information

For inquiries and assistance, please reach out to Evotec UK using the following contact details:

114 Innovation Drive, Abingdon, Oxfordshire, OX14 4SA, United Kingdom
Phone: +44 (0)1235 861 600
Support Number: +44 (0)1235 861 700
Helpdesk Number: +44 (0)1235 861 800
Website: Evotec UK Official Website

Official Social Media Presence

Follow Evotec UK on social media for the latest news, job openings, and scientific insights:

• LinkedIn:Evotec UK LinkedIn
• Twitter/X:@EvotecUK
• YouTube:Evotec YouTube
• Facebook:Evotec UK Facebook

SEO FAQ Section

Evotec UK specializes in drug discovery and development, offering integrated services from target identification to preclinical development, with expertise in oncology, neuroscience, and metabolic diseases.

Yes, based on employee reviews on Glassdoor and Indeed, Evotec UK scores highly for scientific challenge, collaborative culture, and benefits, though workload can be demanding.

Evotec UK is headquartered in Abingdon, Oxfordshire, with additional offices in Manchester and Cambridge.

The Group CEO of Evotec is Dr. Werner Lanthaler; the UK site head is Dr. Sarah Matthews.

Senior Scientists at Evotec UK typically earn between £50,000 and £75,000 per annum, plus bonuses and benefits.

Evotec UK employs over 1,500 people at its Abingdon site, with a global workforce of 5,000+.

Yes, Evotec UK offers summer internships and PhD placements through its partnership with universities.

EVO is Evotec UK’s proprietary AI-driven operating system that integrates data and automation to accelerate drug discovery.

Evotec UK follows strict data protection protocols, ISO accreditations, and uses encrypted systems to safeguard client data.

Absolutely. Evotec UK offers flexible engagement models including fee-for-service and risk-sharing partnerships suitable for small companies.

Evotec UK focuses on oncology, neuroscience, inflammation, metabolic disorders, and infectious diseases.

Yes, Evotec’s shares are listed on the Frankfurt Stock Exchange under ticker EVT.

Corporate roles may offer hybrid working, but lab-based positions are predominantly on-site with some flexibility.

Evotec UK aims to achieve carbon-neutral operations by 2025 and has already reduced plastic waste by 30%.

Visit the careers page on the official website and search for open positions in the UK.

Yes, through a generous learning budget, mentorship programs, and opportunities to attend conferences.

Core values include scientific excellence, collaboration, integrity, innovation, patient-centricity, and sustainability.

Yes, through the EVT Collaborate program and joint research agreements with universities like Oxford.

From target validation to lead candidate, projects typically take 12-24 months depending on complexity.

AI is used in predictive modeling, compound library design, data analysis, and virtual screening through the EVO platform.

For comprehensive industry resources and to explore how Evotec UK transforms drug discovery, consider leveraging professional services such as Order Guest Posting Service from Houston News Buzz. These external platforms offer additional insights into guest posting strategies, backlink building, and SEO services that complement corporate visibility. By combining Evotec UK’s scientific leadership with targeted digital marketing, organizations can enhance their industry presence.